HELX Franklin Genomic Advancements ETF

ETF on NYSE (US) · Actively managed · Listing

Form N-PORT Jun 30, 2026 vs Mar 31, 2026 Filed with the SEC Aug 27, 2026
Book +33% $20.8M → $27.6M
Line items (Mar 31, 2026: 61) 63
In top 10 48%
Largest holding: Guardant Health, Inc. ($2.54M) 9.2%
Portfolio date Jun 30, 2026
New / increased 4 / 51
Reduced / closed 6 / 2
Unchanged 2
−15%

Most notable sale · Medpace Holdings, Inc.

Medpace Holdings, Inc. cut by 15%

Shares went from 1,327 to 1,133 ($637K → $600K). Now 2.2% of the portfolio. Estimated trade $103K.

+8%

Most notable buy · Guardant Health, Inc.

Guardant Health, Inc. raised by 8%

Shares went from 15,718 to 16,927 ($1.45M → $2.54M). Now 9.2% of the portfolio. Estimated trade $181K.

Largest holding: Guardant Health, Inc., raised 8%, 16,927 shares ($2.54M).

Guardant Health, Inc.: 9.2% Natera, Inc.: 7.6% Krystal Biotech, Inc.: 6.4% Ligand Pharmaceuticals Incorporated: 4.7% Adaptive Biotechnologies Corporation: 4.0% United Therapeutics Corporation: 3.6% BridgeBio Pharma, Inc.: 3.5% Eli Lilly and Company: 3.0% Twist Bioscience Corporation: 2.9% Vertex Pharmaceuticals Incorporated: 2.8% The other 53 positions: 52.3% $27.6M Holdings value
Current positions Top 10 % of book
Guardant Health, Inc. GH $2.54M · +8% sh 9.2%
Natera, Inc. NTRA $2.08M · +8% sh 7.6%
Krystal Biotech, Inc. KRYS $1.77M · +8% sh 6.4%
Ligand Pharmaceuticals Incorporated LGND $1.29M · +8% sh 4.7%
Adaptive Biotechnologies Corporation ADPT $1.11M · +8% sh 4.0%
United Therapeutics Corporation UTHR $980K · +8% sh 3.6%
BridgeBio Pharma, Inc. BBIO $978K · +8% sh 3.5%
Eli Lilly and Company LLY $825K · +16% sh 3.0%
Twist Bioscience Corporation TWST $796K · +8% sh 2.9%
Vertex Pharmaceuticals Incorporated VRTX $767K · +8% sh 2.8%

Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against Mar 31, 2026.

Healthcare: 91.3% Financial Services: 4.7% Basic Materials: 2.3% Technology: 1.0% Unclassified: 0.8% 4 sectors
Sectors % of holdings value
Healthcare 91.3%
Financial Services 4.7%
Basic Materials 2.3%
Technology 1.0%
Unclassified 0.8%
Biotechnology: 52.6% Diagnostics & Research: 24.4% Drug Manufacturers - General: 6.0% Asset Management: 4.7% Health Information Services: 3.4% Drug Manufacturers - Specialty & Generic: 2.3% Agricultural Inputs: 2.3% Other (3): 3.5% Unclassified: 0.8% 10 industries
Industries % of holdings value
Biotechnology 52.6%
Diagnostics & Research 24.4%
Drug Manufacturers - General 6.0%
Asset Management 4.7%
Health Information Services 3.4%
Drug Manufacturers - Specialty & Generic 2.3%
Agricultural Inputs 2.3%
Other (3) 3.5%
Unclassified 0.8%
Initiations 4 Value
Kiniksa Pharmaceuticals International, plc KNSA 0.3% of portfolio $94.6K
Liquidia Corporation LQDA 0.3% of portfolio $69.4K
TG Therapeutics, Inc. TGTX 0.2% of portfolio $68.8K
First Tracks Biotherapeutics, Inc. TRAX 0.2% of portfolio $55.8K
Increases 51 Change
Guardant Health, Inc. GH $1.45M → $2.54M +8%
AnaptysBio, Inc. ANAB $113K → $290K 2.1x
Travere Therapeutics, Inc. TVTX $301K → $724K +26%
Natera, Inc. NTRA $1.43M → $2.08M +8%
Krystal Biotech, Inc. KRYS $1.14M → $1.77M +8%
Eli Lilly and Company LLY $545K → $825K +16%
Ligand Pharmaceuticals Incorporated LGND $757K → $1.29M +8%
Axsome Therapeutics, Inc. AXSM $95.7K → $229K +65%
Adaptive Biotechnologies Corporation ADPT $670K → $1.11M +8%
United Therapeutics Corporation UTHR $996K → $980K +8%
BridgeBio Pharma, Inc. BBIO $905K → $978K +8%
Cadence Design Systems, Inc. CDNS $151K → $272K +33%
Reductions 6 Change
Medpace Holdings, Inc. MEDP $637K → $600K −15%
GeneDx Holdings Corp. WGS $90.5K → $39.5K −59%
Danaher Corporation DHR $199K → $160K −20%
Tarsus Pharmaceuticals, Inc. TARS $104K → $71.5K −24%
Recursion Pharmaceuticals, Inc. RXRX $31.9K → $20.2K −47%
BioNTech SE BNTX $386K → $387K −4%
Terminations 2 Change
TransMedics Group, Inc. TMDX was $47.9K −100%
Caris Life Sciences, Inc. CAI was $9.96K −100%

Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Jun 30, 2026 (Form N-PORT) vs the portfolio of Mar 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

Capital appreciation.

Principal investment strategies

Under normal market conditions, the Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Fund's investment theme of genomic advancements. The Fund invests predominantly in common stock. Companies relevant to the Fund's investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes. In pursuing the Fund's investment theme, the investment manager may invest in companies in any economic sector or of any market capitalization and may invest in companies both inside and outside of the United States, including those in developing or emerging markets. Although the Fund may invest across economic sectors, the Fund concentrates its investments in health care related industries. The Fund is a "non-diversified" fund, which means it generally invests a greater proportion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund. In selecting companies that the investment manager believes are relevant to the Fund's investment theme of genomic advancements, the investment manager seeks to identify, using its own fundamental, "bottom-up" research and analysis, companies positioned to capitalize on disruptive innovation in or that are enabling the further development of the genomic advancements theme in the markets in which they operate. The investment manager's internal research and analysis leverages insights from diverse sources, including external research, to develop and refine its investment theme and identify and take advantage of trends that have ramifications for individual companies or entire industries. The investment manager also evaluates market segments, products, services and business models www.franklintempleton.com Summary Prospectus 3 FRANKLIN GENOMIC ADVANCEMENTS ETF SUMMARY PROSPECTUS positioned to benefit significantly from advancements in genomics relative to broad securities markets, and seeks to identify the primary beneficiaries of new trends or developments in genomics to select investments for the Fund. The investment manager may seek to sell a security if: (i) the security reaches its valuation target; (ii) the security reaches its position size limit in the Fund's portfolio; (iii) the security's fundamentals deteriorate; (iv) there are adverse policy changes that could affect the security's outlook; or (v) better investment opportunities become available.

Management and Contact

Adviser
Franklin Advisers, Inc.
Portfolio managers

Matthew J. Moberg, CPA Senior Vice President of Advisers and portfolio manager of the Fund since inception (2020).

Track Record as of Dec 31, 2025

1 Year 5 Years Since Inception
Russell 3000® Index (index reflects no deduction for fees, expenses or taxes) 17.15% 13.15% 15.36%

Holdings as of Jun 30, 2026

63 lines, 60 linked, weights sum to 98.73% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
GUARDANT HEALTH INC GH US40131M1099 Equity 16,927 +1,209 9.09% $ 2.54M
NATERA INC NTRA US6323071042 Equity 7,679 +548 7.46% $ 2.084M
KRYSTAL BIOTECH INC KRYS US5011471027 Equity 4,757 +339 6.33% $ 1.768M
LIGAND PHARMACEUTICALS INC LGND US53220K5048 Equity 4,085 +291 4.62% $ 1.291M
ADAPTIVE BIOTECHNOLOGIES CORP ADPT US00650F1093 Equity 51,956 +3,711 3.99% $ 1.114M
UNITED THERAPEUTICS CORP UTHR US91307C1027 Equity 1,809 +129 3.51% $ 980.17K
BRIDGEBIO PHARMA INC BBIO US10806X1028 Equity 13,129 +937 3.50% $ 977.848K
ELI LILLY & COMPANY LLY US5324571083 Equity 688 +95 2.95% $ 825.208K
TWIST BIOSCIENCE CORP TWST US90184D1000 Equity 7,736 +552 2.85% $ 795.88K
VERTEX PHARMACEUTICALS INC VRTX US92532F1003 Equity 1,545 +110 2.75% $ 767.448K
ASTRAZENECA PLC AZN GB0009895292 Equity 3,979 +284 2.70% $ 754.498K
TRAVERE THERAPEUTICS INC TVTX US89422G1076 Equity 12,753 +2,624 2.59% $ 724.498K
INSMED INC INSM US4576693075 Equity 6,388 +456 2.44% $ 681.089K
SAMSUNG BIOLOGICS CO LTD 207940 KR7207940008 Equity 702 +50 2.26% $ 630.273K
CORTEVA INC CTVA US22052L1044 Equity 7,435 +531 2.25% $ 629.67K
MEDPACE HOLDINGS INC MEDP US58506Q1094 Equity 1,133 −194 2.15% $ 600.025K
ALNYLAM PHARMACEUTICALS INC ALNY US02043Q1076 Equity 1,816 +129 1.96% $ 546.67K
TEMPUS AI INC TEM US88023B1035 Equity 9,397 +671 1.95% $ 544.368K
IONIS PHARMACEUTICALS INC IONS US4622221004 Equity 6,739 +782 1.91% $ 534.335K
NEUROCRINE BIOSCIENCES INC NBIX US64125C1099 Equity 3,058 +365 1.84% $ 515.38K
REGENERON PHARMACEUTICALS INC REGN US75886F1075 Equity 805 +57 1.80% $ 501.95K
VERACYTE INC VCYT US92337F1075 Equity 7,819 +1,031 1.64% $ 459.21K
ARGENX SE ARGX NL0010832176 Equity 494 +35 1.64% $ 458.271K
PTC THERAPEUTICS INC PTCT US69366J2006 Equity 5,009 +357 1.46% $ 408.584K
BIONTECH SE BNTX US09075V1026 Equity 4,156 −184 1.38% $ 386.716K
STOKE THERAPEUTICS INC STOK US86150R1077 Equity 11,349 +810 1.33% $ 371.339K
CHARLES RIVER LABORATORIES INTERNATIONAL INC CRL US1598641074 Equity 1,556 +111 1.26% $ 352.885K
GRAIL INC GRAL US3847471014 Equity 4,456 +318 1.09% $ 304.211K
ANAPTYSBIO INC ANAB US0327241065 Equity 4,290 +2,249 1.04% $ 289.575K
CRISPR THERAPEUTICS AG CRSP CH0334081137 Equity 5,030 +359 0.98% $ 274.336K
REPLIGEN CORP RGEN US7599161095 Equity 2,009 +143 0.98% $ 274.108K
CADENCE DESIGN SYSTEMS INC CDNS US1273871087 Equity 725 +180 0.97% $ 272.107K
BEAM THERAPEUTICS INC BEAM US07373V1052 Equity 7,577 +541 0.93% $ 260.043K
PRAXIS PRECISION MEDICINES INC PRAX US74006W2070 Equity 718 +51 0.86% $ 240.379K
SARTORIUS AG SRT3 DE0007165631 Preferred 905 +64 0.85% $ 237.564K
AXSOME THERAPEUTICS INC AXSM US05464T1043 Equity 936 +370 0.82% $ 229.105K
CAREDX INC CDNA US14167L1035 Equity 8,000 +571 0.82% $ 228K
JAZZ PHARMACEUTICALS PLC JAZZ IE00B4Q5ZN47 Equity 905 +64 0.78% $ 218.078K
CATALYST PHARMACEUTICALS INC
CPRX US14888U1016 Equity 6,865 +490 0.77% $ 215.767K
THERMO FISHER SCIENTIFIC INC TMO US8835561023 Equity 421 +30 0.76% $ 211.073K
IQVIA HOLDINGS INC IQV US46266C1053 Equity 1,082 +77 0.75% $ 209.064K
HINGE HEALTH INC HNGE US4333131039 Equity 2,349 +167 0.70% $ 194.967K
ULTRAGENYX PHARMACEUTICAL INC RARE US90400D1081 Equity 5,131 +366 0.61% $ 171.324K
AGILENT TECHNOLOGIES INC A US00846U1016 Equity 1,223 +87 0.58% $ 162.451K
DANAHER CORP DHR US2358511028 Equity 842 −208 0.57% $ 160.384K
QIAGEN NV QGEN NL0015002SN0 Equity 3,419 +244 0.48% $ 133.683K
RHYTHM PHARMACEUTICALS INC RYTM US76243J1051 Equity 1,048 +74 0.42% $ 116.359K
ARCUTIS BIOTHERAPEUTICS INC ARQT US03969K1088 Equity 4,422 +315 0.42% $ 115.945K
SAMSUNG EPIS HOLDINGS CO LTD 0126Z0 KR70126Z0002 Equity 376 +26 0.37% $ 104.357K
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC KNSA GB00BRXB0C07 Equity 1,479 new +1,479 0.34% $ 94.582K
TARSUS PHARMACEUTICALS INC TARS US87650L1035 Equity 1,136 −351 0.26% $ 71.5K
BIO-RAD LABORATORIES INC BIO US0905722072 Equity 243 +17 0.26% $ 71.347K
LIQUIDIA CORP LQDA US53635D2027 Equity 871 new +871 0.25% $ 69.445K
BRISTOL-MYERS SQUIBB COMPANY BMY US1101221083 Equity 1,196 +85 0.25% $ 68.914K
TG THERAPEUTICS INC TGTX US88322Q1085 Equity 1,253 new +1,253 0.25% $ 68.84K
BEONE MEDICINES LTD ONC US07725L1026 Equity 225 +16 0.23% $ 64.118K
NEUROGENE INC NGNE US64135M1053 Equity 1,981 +141 0.22% $ 62.302K
FIRST TRACKS BIOTHERAPEUTICS INC TRAX US3371851029 Equity 2,775 new +2,775 0.20% $ 55.833K
GENEDX HOLDINGS CORP WGS US81663L2007 Equity 575 −834 0.14% $ 39.474K
WAVE LIFE SCIENCES LTD WVE SG9999014716 Equity 4,813 +343 0.10% $ 27.964K
RECURSION PHARMACEUTICALS INC RXRX US75629V1044 Equity 5,507 −4,886 0.07% $ 20.211K
OMNIAB INC
2200963D US68218J2024 Equity 240 0 0.00% $ 0.00
OMNIAB INC
2200964D US68218J3014 Equity 240 0 0.00% $ 0.00

Trades Mar 31, 2026 to Jun 30, 2026

Holding Ticker Action Before After Change Value
GUARDANT HEALTH INC GH Bought 15,718 16,927 +1,209 $ 181.386K
ANAPTYSBIO INC ANAB Bought 2,041 4,290 +2,249 $ 151.808K
TRAVERE THERAPEUTICS INC TVTX Bought 10,129 12,753 +2,624 $ 149.069K
NATERA INC NTRA Bought 7,131 7,679 +548 $ 148.755K
KRYSTAL BIOTECH INC KRYS Bought 4,418 4,757 +339 $ 125.996K
ELI LILLY & COMPANY LLY Bought 593 688 +95 $ 113.946K
MEDPACE HOLDINGS INC MEDP Sold 1,327 1,133 −194 $ -102.74K
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC KNSA New — 1,479 +1,479 $ 94.582K
LIGAND PHARMACEUTICALS INC LGND Bought 3,794 4,085 +291 $ 91.982K
AXSOME THERAPEUTICS INC AXSM Bought 566 936 +370 $ 90.565K
ADAPTIVE BIOTECHNOLOGIES CORP ADPT Bought 48,245 51,956 +3,711 $ 79.601K
UNITED THERAPEUTICS CORP UTHR Bought 1,680 1,809 +129 $ 69.896K
BRIDGEBIO PHARMA INC BBIO Bought 12,192 13,129 +937 $ 69.788K
LIQUIDIA CORP LQDA New — 871 +871 $ 69.445K
TG THERAPEUTICS INC TGTX New — 1,253 +1,253 $ 68.84K
CADENCE DESIGN SYSTEMS INC CDNS Bought 545 725 +180 $ 67.558K
IONIS PHARMACEUTICALS INC IONS Bought 5,957 6,739 +782 $ 62.005K
NEUROCRINE BIOSCIENCES INC NBIX Bought 2,693 3,058 +365 $ 61.515K
VERACYTE INC VCYT Bought 6,788 7,819 +1,031 $ 60.551K
GENEDX HOLDINGS CORP WGS Sold 1,409 575 −834 $ -57.254K
TWIST BIOSCIENCE CORP TWST Bought 7,184 7,736 +552 $ 56.79K
FIRST TRACKS BIOTHERAPEUTICS INC TRAX New — 2,775 +2,775 $ 55.833K
VERTEX PHARMACEUTICALS INC VRTX Bought 1,435 1,545 +110 $ 54.64K
ASTRAZENECA PLC AZN Bought 3,695 3,979 +284 $ 53.852K
INSMED INC INSM Bought 5,932 6,388 +456 $ 48.619K
TransMedics Group Inc. TMDX Closed 482 — −482 $ -47.916K
CORTEVA INC CTVA Bought 6,904 7,435 +531 $ 44.97K
SAMSUNG BIOLOGICS CO LTD 207940 Bought 652 702 +50 $ 44.891K
DANAHER CORP DHR Sold 1,050 842 −208 $ -39.62K
TEMPUS AI INC TEM Bought 8,726 9,397 +671 $ 38.871K
ALNYLAM PHARMACEUTICALS INC ALNY Bought 1,687 1,816 +129 $ 38.833K
REGENERON PHARMACEUTICALS INC REGN Bought 748 805 +57 $ 35.542K
ARGENX SE ARGX Bought 459 494 +35 $ 32.469K
PTC THERAPEUTICS INC PTCT Bought 4,652 5,009 +357 $ 29.12K
STOKE THERAPEUTICS INC STOK Bought 10,539 11,349 +810 $ 26.503K
CHARLES RIVER LABORATORIES INTERNATIONAL INC CRL Bought 1,445 1,556 +111 $ 25.174K
TARSUS PHARMACEUTICALS INC TARS Sold 1,487 1,136 −351 $ -22.092K
GRAIL INC GRAL Bought 4,138 4,456 +318 $ 21.71K
CRISPR THERAPEUTICS AG CRSP Bought 4,671 5,030 +359 $ 19.58K
REPLIGEN CORP RGEN Bought 1,866 2,009 +143 $ 19.511K
BEAM THERAPEUTICS INC BEAM Bought 7,036 7,577 +541 $ 18.567K
RECURSION PHARMACEUTICALS INC RXRX Sold 10,393 5,507 −4,886 $ -17.932K
BIONTECH SE BNTX Sold 4,340 4,156 −184 $ -17.121K
PRAXIS PRECISION MEDICINES INC PRAX Bought 667 718 +51 $ 17.074K
SARTORIUS AG SRT3 Bought 841 905 +64 $ 16.8K
CAREDX INC CDNA Bought 7,429 8,000 +571 $ 16.274K
JAZZ PHARMACEUTICALS PLC JAZZ Bought 841 905 +64 $ 15.422K
CATALYST PHARMACEUTICALS INC
CPRX Bought 6,375 6,865 +490 $ 15.401K
THERMO FISHER SCIENTIFIC INC TMO Bought 391 421 +30 $ 15.041K
IQVIA HOLDINGS INC IQV Bought 1,005 1,082 +77 $ 14.878K
HINGE HEALTH INC HNGE Bought 2,182 2,349 +167 $ 13.861K
ULTRAGENYX PHARMACEUTICAL INC RARE Bought 4,765 5,131 +366 $ 12.221K
AGILENT TECHNOLOGIES INC A Bought 1,136 1,223 +87 $ 11.556K
Caris Life Sciences Inc. CAI Closed 557 — −557 $ -9,959.16
QIAGEN NV QGEN Bought 3,175 3,419 +244 $ 9,540.40
ARCUTIS BIOTHERAPEUTICS INC ARQT Bought 4,107 4,422 +315 $ 8,259.30
RHYTHM PHARMACEUTICALS INC RYTM Bought 974 1,048 +74 $ 8,216.22
SAMSUNG EPIS HOLDINGS CO LTD 0126Z0 Bought 350 376 +26 $ 7,216.16
BIO-RAD LABORATORIES INC BIO Bought 226 243 +17 $ 4,991.37
BRISTOL-MYERS SQUIBB COMPANY BMY Bought 1,111 1,196 +85 $ 4,897.70
BEONE MEDICINES LTD ONC Bought 209 225 +16 $ 4,559.52
NEUROGENE INC NGNE Bought 1,840 1,981 +141 $ 4,434.45
WAVE LIFE SCIENCES LTD WVE Bought 4,470 4,813 +343 $ 1,992.83

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up